Dulaglutide

度拉糖肽

Report date: 2026/02/11 20:01:36

Base Information

Drug NameDulaglutide
Drug Alias Namedulaglutida杜拉鲁肽度拉鲁肽dulaglutidedulaglutidum +[9] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsIschemic StrokeMenstruation DisturbancesEndocrine System Diseases +[17] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date2014/09/18
Country/TerritoryCzechiaBelgiumBulgaria +[45] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And CompanyVanderbilt University Medical CenterAin Shams University +[6] 
Inactive CompaniesEli Lilly Italia SpaVetter Pharma-Fertigung Gmbh & Co KgCatalent Germany Schorndorf Gmbh +[6] 
Active IndicationsIschemic StrokeMenstruation DisturbancesGlucose Intolerance +[14] 
Inactive IndicationsEndocrine System DiseasesVascular DiseasesCardiovascular Diseases

Other Information

ATC CodeA10BJ05
Related LinksWikipediaDrugBankKEGG